Cesca Therapeutics Inc. (NASDAQ:KOOL) Issues Favorable 40-Month Follow-Up Results Of SurgWerks Feasibility Study
Cesca Therapeutics Inc. (NASDAQ:KOOL) has disclosed on Wednesday 40-month follow-up results of its feasibility study evaluating SurgWerks for the treatment of late-stage, no-option critical limb […]